Absci reports prelim FY2023 revenue $5.7M, cash $97.7M; proposes public offering

Absci Corp

Preliminary Q4 revenue ~$0.3M, FY revenue ~$5.7M; operating expenses $120-122M incl $21.3M goodwill impairment.
Unrestricted cash/short-term investments $97.7M as of Dec 31, 2023.
Filed preliminary prospectus for underwritten public offering of common stock (undisclosed size).
16 Active Programs with partners including AstraZeneca, Almirall, Merck; ABS-101 IND submission planned Q1 2025.
ABS-101 IND-enabling studies started Feb 2024; Phase 1 potentially H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.